Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	63.57	83.6	7.35	16.05
Cash & Short-Term Investments	63.57	83.6	7.35	16.05
Cash Growth	347.43%	1037.44%	-54.21%	-
Accounts Receivable	-	0.36	-	-
Other Receivables	2.22	1.98	-	-
Receivables	2.22	2.34	-	-
Prepaid Expenses	1.15	2.3	0.2	0.47
Total Current Assets	66.94	88.23	7.55	16.52
Total Assets	66.94	88.23	7.55	16.52
Accounts Payable	3.48	4.59	0.94	3.18
Accrued Expenses	3.56	4.29	1.26	2.44
Other Current Liabilities	3.27	3.17	0.17	0.16
Total Current Liabilities	10.31	12.04	2.36	5.78
Long-Term Debt	16.02	11.94	8.05	32.42
Other Long-Term Liabilities	1.92	1.65	1.01	1.5
Total Liabilities	28.26	25.63	11.43	39.7
Common Stock	0.01	0.01	-	-
Additional Paid-In Capital	161.3	156.33	1.82	1.22
Retained Earnings	-122.74	-93.74	-76.3	-94.99
Comprehensive Income & Other	0.1	0	-	-
Total Common Equity	38.68	62.61	-74.48	-93.78
Shareholders' Equity	38.68	62.61	-3.88	-23.17
Total Liabilities & Equity	66.94	88.23	7.55	16.52
Total Debt	16.02	11.94	8.05	32.42
Net Cash (Debt)	47.55	71.66	-0.7	-16.36
Net Cash Per Share	5.18	32.19	-0.39	-2.86
Filing Date Shares Outstanding	11.84	11.02	5.72	5.72
Total Common Shares Outstanding	11.09	11.01	5.72	5.72
Working Capital	56.63	76.2	5.19	10.74
Book Value Per Share	3.49	5.69	-13.02	-16.40
Tangible Book Value	38.68	62.61	-74.48	-93.78
Tangible Book Value Per Share	3.49	5.69	-13.02	-16.40

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q